Recent Updates
Recently added Catalysts
Fairmount Funds Management 13F Holdings (Q2 2026)
According to its SEC 13F filed on Aug 14, 2026, Fairmount Funds Management reported 12 long positions worth $1.51B as of Jun 30, 2026. ORKA is 23.3% of the portfolio and the top 10 holdings are 98%. Against Q1 2026 it opened 1 new positions, added to 1, trimmed 0 and exited 1. 1 holdings have a dated FDA decision or data readout in the next 90 days, and 7 more expect one in a stated window such as "H2 2026".
Catalysts ahead in this portfolio
Dated FDA decisions and data readouts for its holdings in the next 90 days, with our probability of approval
Portfolio over time
13F value by quarter, Q1 2021 to Q2 2026
By company stage (share of value)
Holdings
Every position in the 13F, with the change since the fund's previous filing, how many of the 45 specialist funds also own it, and its next FDA catalyst. Option positions are labelled CALL or PUT.
| Stock | Company Name | Shares Held | Market Value | % of Portfolio | QoQ Change | Position Change | Also Held By | Stage | Next Catalyst |
|---|---|---|---|---|---|---|---|---|---|
 ORKA | ORUKA THERAPEUTICS INC | 3.71 M | 352.63 M | 23.3 | Unchanged | Clinical | Expected 2026-12 Phase 2a data readout | ||
 APGE | APOGEE THERAPEUTICS INC | 298.65 K | 39.64 M | 2.6 | Unchanged | Clinical | Expected 2H 2026 Phase 1b data readout | ||
 ZBIO | ZENAS BIOPHARMA INC | 2.36 M | 59.87 M | 4 | Unchanged | Clinical | Expected 2026 IND Submission | ||
 FTH | FAETH THERAPEUTICS INC | 722.02 K | 18.05 M | 1.2 | New | Clinical | Expected H2 2026 Phase 2 topline data readout | ||
 ELVN | ENLIVEN THERAPEUTICS INC | 1.86 M | 94.17 M | 6.2 | Unchanged | Clinical | None in 90 days | ||
 IKT | INHIBIKASE THERAPEUTICS INC | 8.63 M | 17.51 M | 1.2 | Unchanged | Clinical | Expected by end of 2026 Phase 2 topline data readout |
Top 20 Holdings
Size = share of the portfolio. Option positions show CALL or PUT.
Who else owns these stocks?
All Stock Holdings ranks every biotech stock by how many of the 45 specialist funds own it, and whether that number rose or fell this quarter. Click "of 45 funds" on any row above, or open the full view.
Questions about Fairmount Funds Management's 13F
What does Fairmount Funds Management own?
12 stocks worth $1.51B at Jun 30, 2026, as reported in its 13F, led by ORKA (23.3% of the portfolio). The full list is in the Holdings table above.
What did it buy and sell last quarter?
Against Q1 2026: 1 new positions, 1 increases, 0 reductions and 1 full exits, from its 13F filings.
How current is this data?
13F filings are due 45 days after each quarter ends, so they show positions at quarter end, not today. The next filing (Q3 2026) is due Nov 16, 2026.
Why are some positions labelled CALL or PUT?
Those are option positions (calls and puts). The 13F reports them as the shares underlying the option, with no strike or expiry, so they are listed apart from share positions.
Source: SEC EDGAR Form 13F-HR filed by Fairmount Funds Management LLC, accession 0001104659-26-096405, filed Aug 14, 2026. Values as filed; option positions are shown at the value of the underlying shares and labelled CALL or PUT.